Frontal parenchymal atrophy measures in multiple sclerosis

2004 ◽  
Vol 10 (5) ◽  
pp. 562-568 ◽  
Author(s):  
Laura Locatelli ◽  
Robert Zivadinov ◽  
Attilio Grop ◽  
Marino Zorzon
Keyword(s):  
Multiple Sclerosis ◽  
Cognitive Functions ◽  
Brain Atrophy ◽  
Neuropsychological Functioning ◽  
Intraclass Correlation ◽  
Quantitative Mri ◽  
Cross Sectional ◽  
Regional Brain ◽  
Brain Parenchymal Fraction ◽  
Brain Parenchymal

The aim of this study was to establish whether, in a cross-sectional study, the normalized measures of whole and regional brain atrophy correlate better with tests assessing the cognitive function than the absolute brain atrophy measures. The neuropsychological performances and disability have been assessed in 39 patients with relapsing-remitting multiple sclerosis (MS). T1- and T2-lesion load (LL) of total brain and frontal lobes (FLs) were measured using a reproducible semiautomated technique. The whole brain volume and the regional brain parenchymal volume (RBPV) of FLs were obtained using a computerized interactive program, which incorporates semiautomated and automated segmentation processes. Normalized measures of brain atrophy, i.e., brain parenchymal fraction (BPF) and regional brain parenchymal fraction (RBPF) of FLs, were calculated. The scan-rescan, inter- and intrarater coefficient of variation (COV) and intraclass correlation coefficient (ICC) have been estimated. The RBPF of FLs showed an acceptable level of reproducibility which ranged from 1.7% for intrarater variability to 3.2% for scan-rescan variability. The mean ICC was 0.88 (CI 0.82-0.93). The RBPF of FLs demonstrated stronger magnitudes of correlation with neuropsychological functioning, disability and quantitative MRI lesion measures than RBPV. These differences were statistically significant: P=0.001 for Stroop Color Word Interference test, P=0.001 for Paced Auditory Serial Addition Test, P=0.04 for Standard Raven Progressive Matrices, P=0.049 for Expanded Disability Status Scale, P=0.01 for T2-LL of FLs and P< 0.001 for T1-LL of FLs. BPF demonstrated significant correlations with tests assessing cognitive functions, whereas BPAV did not. The correlation analysis results were supported by the results of multiple regression analysis which showed that only the normalized brain atrophy measures were associated with tests exploring the cognitive functions. These data suggest that RBPF is a reproducible and sensitive method for measuring frontal parenchymal atrophy. The normalized measures of whole and regional brain parenchymal atrophy should be preferred to absolute measures in future studies that correlate neuropsychological performances and brain atrophy measures in patients with MS.

Has your patient's multiple sclerosis lesion burden or brain atrophy actually changed?

2004 ◽  
Vol 10 (4) ◽  
pp. 402-406 ◽  
Author(s):  
Xingchang Wei ◽  
Charles RG Guttmann ◽  
Simon K Warfield ◽  
Michael Eliasziw ◽  
J Ross Mitchell
Keyword(s):  
Multiple Sclerosis ◽  
Measurement Error ◽  
Brain Tissue ◽  
Brain Atrophy ◽  
Multiple Sclerosis Lesion ◽  
Lesion Volume ◽  
Measurement Variability ◽  
Brain Parenchymal Fraction ◽  
Significant Change ◽  
Brain Parenchymal

Changes in mean magnetic resonance imaging (MRI)-derived measurements between patient groups are often used to determine outcomes in therapeutic trials and other longitudinal studies of multiple sclerosis (MS). However, in day-to-day clinical practice the changes withinindividual patients may also be of interest. In this paper, we estimated the measurement error of an automated brain tissue quantification algorithm and determined the thresholds for statistically significant change of MRI-derived T2 lesion volume and brain atrophy in individual patients. Twenty patients with MS were scanned twice within 30 min. Brain tissue volumes were measured using the computer algorithm. Brain atrophy was estimated by calculation of brain parenchymal fraction. The threshold of change between repeated scans that represented statistically significant change beyond measurement error with 95% certainty was 0.65 mL for T2 lesion burden and 0.0056 for brain parenchymal fraction. Changes in lesion burden and brain atrophy below these thresholds can be safely (with 95% certainty) explained by measurement variability alone. These values provide clinical neurologists with a useful reference to interpret MRI-derived measures in individual patients.

scholarly journals Relationship Between Interpersonal Deressive Symptoms and Reduced Amygdala Volume in People with Multiple Sclerosis: Considerations for Clinical Practice

2020 ◽  
Author(s):  
Sarah Haines ◽  
Ernest Butler ◽  
Stephen Stuckey ◽  
Robert Hester ◽  
Lisa B. Grech
Keyword(s):  
Multiple Sclerosis ◽  
Brain Atrophy ◽  
Depression Scale ◽  
Hippocampal Volume ◽  
Epidemiological Studies ◽  
Cross Sectional ◽  
Regional Brain ◽  
Amygdala Volume ◽  
The Right ◽  
Regional Brain Atrophy

Abstract Background: The lifetime prevalence of depression in people with multiple sclerosis (MS) is approximately 50% compared with around 16% in the general population. There is a relationship between depression and quality of life in people with MS and evidence that depression may contribute to disease progression. Methods: This cross-sectional pilot study assessed the association between depression and regional brain atrophy, including amygdala and hippocampal volume. Forty-nine participants with MS recruited through a hospital MS clinic were administered the Center for Epidemiological Studies Depression Scale Revised (CESD-R) to investigate whether higher endorsement on the items depressive affect and interpersonal symptoms were associated with volumetric magnetic resonance imaging measurements of hippocampal and amygdala atrophy. Results: Regression analysis revealed an association between depression-related interpersonal symptoms and right amygdala volume. No association was found between depression and hippocampal volume. Conclusions: These results provide preliminary support for a unilateral, biologically based relationship between the right amygdala and characteristic interpersonal depressive symptoms expressed by people with MS and add to the growing body of literature implicating regional brain atrophy in MS-associated depression. Given that the interpersonal subcomponent of the CESD-R measures social functioning, and the neural networks in the amygdala are known to be implicated in processing social stimuli, this research suggests that targeted diagnosis and treatments for depression in people with MS may be particularly beneficial in this population. Further confirmatory research of this relationship is required.

Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients

2000 ◽  
Vol 6 (6) ◽  
pp. 373-377 ◽  
Author(s):  
E Fisher ◽  
R A Rudick ◽  
G Cutter ◽  
M Baier ◽  
D Miller ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Progression ◽  
Brain Atrophy ◽  
Phase Iii ◽  
Phase Iii Trial ◽  
Follow Up Study ◽  
Relapsing Remitting ◽  
Brain Parenchymal Fraction ◽  
Brain Parenchymal

Brain atrophy measurement can provide an estimate of the amount of tissue destruction due to the pathologic processes in multiple sclerosis. The potential usefulness of atrophy as a marker of disease progression depends upon the concurrent and predictive relationships between atrophy and disability. A follow-up study was performed to measure atrophy and disability scores in patients from the Multiple Sclerosis Collaborative Research Group's phase III trial of IFNb-1a (Avonex) in relapsing-remitting multiple sclerosis. New data were obtained on 160 out of 172 eligible patients from the original trial were enrolled in the follow-up study approximately 8 years after randomization. The follow-up visit consisted of several tests and questionnaires including a clinical exam to determine Expanded Disability Status Score (EDSS) and Multiple Sclerosis Functional Composite (MSFC), and a magnetic resonance imaging exam to calculate the brain parenchymal fraction. Brain parenchymal fraction was correlated with both EDSS and MSFC at each of the four time points for which data were available (baseline 1, 2 and 8 years). Furthermore, the change in BPF was correlated with the changes in disability scores from the end of the phase III trial to the follow-up exam. These data suggest that brain atrophy may be a useful and clinically relevant marker of disease progression in relapsing-remitting MS.

scholarly journals Cognitive disorders in multiple sclerosis: correlation between neuropsychological, neurophysiological and neuroimaging characteristics

2008 ◽  
Vol 7 (5-1) ◽  
pp. 252-259
Author(s):  
N. F. Musina
Keyword(s):  
Magnetic Resonance Imaging ◽  
Multiple Sclerosis ◽  
Cognitive Functions ◽  
Brain Atrophy ◽  
Mini Mental State Examination ◽  
Cognitive Disorders ◽  
Frontal Assessment Battery ◽  
Resonance Imaging ◽  
State Examination

Multiple sclerosis (MS) — autoimmune disease of CNS, characterized by myelin destruction and axonal damage. To study cognitive functions, the authors used the Mini-Mental State Examination (MMSE), the frontal assessment battery, the procedure developed by A.R. Luriya, neurophysiological characteristics. 71 patients were underwent magnetic resonance imaging. The aim of the study was to analyse the parameters of neuropsychological method, cognitive evoked potentials P300 and the role of brain atrophy in MS. The cognitive functions, the activity of the disease and the expression of brain atrophy are bound by the certain way.

Sign in / Sign up

Export Citation Format

Share Document